{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:20:54Z","timestamp":1790216454203,"version":"4.1.0"},"reference-count":24,"publisher":"Frontiers Media SA","content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2017.01247","type":"journal-article","created":{"date-parts":[[2017,10,5]],"date-time":"2017-10-05T07:56:42Z","timestamp":1507190202000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Predicting Risk of Infection in Patients with Newly Diagnosed Multiple Myeloma: Utility of Immune Profiling"],"prefix":"10.3389","volume":"8","author":[{"given":"Benjamin W.","family":"Teh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon J.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cody Charles","family":"Allison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica A.","family":"Slavin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Spelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon J.","family":"Worth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin A.","family":"Thursky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ritchie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Pellegrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2017,10,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"225","DOI":"10.4065\/mcp.2009.0426","article-title":"Patterns of multiple myeloma during the past 5 decades: stable incidence rates for all age groups in the population but rapidly changing age distribution in the clinic","volume":"85","author":"Turesson","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"B2","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.blre.2014.01.004","article-title":"Changing treatment paradigms for patients with plasma cell myeloma: impact upon immune determinants of infection","volume":"28","author":"Teh","year":"2014","journal-title":"Blood Rev"},{"key":"B3","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ejca.2016.07.025","article-title":"Infection risk with immunomodulatory and proteasome inhibitor-based therapies across treatment phases for multiple myeloma: a systematic review and meta-analysis","volume":"67","author":"Teh","year":"2016","journal-title":"Eur J Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"9219","DOI":"10.1200\/JCO.2005.03.2086","article-title":"Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002 \u2013 Medical Research Council Adult Leukaemia Working Party","volume":"23","author":"Augustson","year":"2005","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1111\/bjh.13532","article-title":"Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy","volume":"171","author":"Teh","year":"2015","journal-title":"Br J Haematol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1200\/JCO.2011.37.2649","article-title":"Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma","volume":"30","author":"Lonial","year":"2012","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/S1470-2045(13)70398-X","article-title":"Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study","volume":"14","author":"Dimopoulos","year":"2013","journal-title":"Lancet Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1182\/blood-2014-03-563759","article-title":"Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study","volume":"124","author":"Bringhen","year":"2014","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/infdis\/161.3.397","article-title":"From the Immunocompromised Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. Report of a consensus panel","volume":"161","author":"Society","year":"1990","journal-title":"J Infect Dis"},{"key":"B11","article-title":"Definitions of infectious diseases and complications after stem cell transplant","author":"Cordonnier","year":"2001","journal-title":"European Society for Blood and Marrow Transplantation"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"key":"B13","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE)","year":"2009"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"key":"B15","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.clim.2011.05.008","article-title":"Assessing immune function by profiling cytokine release from stimulated blood leukocytes and the risk of infection in rheumatoid arthritis","volume":"141","author":"Krause","year":"2011","journal-title":"Clin Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.aaa4268","article-title":"Interleukin-3 amplifies acute inflammation and is a potential therapeutic target in sepsis","volume":"347","author":"Weber","year":"2015","journal-title":"Science"},{"key":"B17","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.exphem.2010.06.012","article-title":"The cytokine\/chemokine pattern in the bone marrow environment of multiple myeloma patients","volume":"38","author":"Cao","year":"2010","journal-title":"Exp Hematol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"920","DOI":"10.3109\/10428191003699563","article-title":"Dysregulation in T helper 1\/T helper 2 cytokine ratios in patients with multiple myeloma","volume":"51","author":"Sharma","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e58504","DOI":"10.1371\/journal.pone.0058504","article-title":"The systemic cytokine environment is permanently altered in multiple myeloma","volume":"8","author":"Zheng","year":"2013","journal-title":"PLoS One"},{"key":"B20","doi-asserted-by":"publisher","first-page":"7474","DOI":"10.1128\/JVI.00658-14","article-title":"Anti-inflammatory cytokines directly inhibit innate but not adaptive CD8+ T cell functions","volume":"88","author":"Freeman","year":"2014","journal-title":"J Virol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1080\/10428190500472503","article-title":"Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections","volume":"47","author":"Sch\u00fctt","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"B22","doi-asserted-by":"publisher","first-page":"i5","DOI":"10.1093\/jac\/dkq437","article-title":"Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients","volume":"66","author":"Pagano","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"B23","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/j.1445-5994.2010.02340.x","article-title":"Use of empiric antimicrobial therapy in neutropenic fever. Australian Consensus Guidelines 2011 Steering Committee","volume":"41","author":"Tam","year":"2011","journal-title":"Intern Med J"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial","volume":"14","author":"San Miguel","year":"2013","journal-title":"Lancet Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2017.01247\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,10,5]],"date-time":"2017-10-05T07:56:45Z","timestamp":1507190205000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2017.01247\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,5]]},"references-count":24,"alternative-id":["10.3389\/fimmu.2017.01247"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2017.01247","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,5]]},"article-number":"1247"}}